{"id":{"repo_id":"greece","oai_identifier":"oai:10442/36062"},"canonical_url":"https://search.ndltd.org/etd/greece/oai:10442/36062","repository":{"repo_id":"greece","name":"Greek National Archive of PhD Theses","base_url":"https://phdtheses.ekt.gr/eadd_oai/request"},"display":{"title":"In vivo μελέτη της δράσης των αναστολέων της κυκλοοξυγενάσης σε πειραματικό μοντέλο καρκινογένεσης του στόματος","abstract":"The purpose of the present study was to explore sulindac’s in vivo effects on oral squamous cell carcinoma (SCC) oncogenesis using the hamster cheek pouch oral carcinogenesis model (HOCM). Thirty Syrian golden hamsters were divided into 3 experimental and 2 control groups (n=6 each). The animals’ right buccal pouches were treated with carcinogen for 9 weeks in one experimental and one control group and for 14 weeks in all other 3 groups. The animals of 2 experimental groups received sulindac from the 1st week and those of the third experimental group from the 10th week. After the end of carcinogenesis treated buccal pouches were removed and examined. In animals treated with carcinogen for 14 weeks development of oral SCC and tumor volume were significantly lower in animals that received sulindac from the first week of the experiment. Oral SCC developing in animals that received sulindac were more frequently well differentiated compared to the control group. In animals treated with carcinogen for 9 weeks the animals that received sulindac developed lower grade of epithelial dysplasia. Proliferation index Ki-67 and positivity for the antiapoptotic molecule survivin were lower in the animals that received sulindac. In conclusion, sulindac appears to exert antineoplastic effects in vivo in the HOCM.","abstract_html":"The purpose of the present study was to explore sulindac’s in vivo effects on oral squamous cell carcinoma (SCC) oncogenesis using the hamster cheek pouch oral carcinogenesis model (HOCM). Thirty Syrian golden hamsters were divided into 3 experimental and 2 control groups (n=6 each). The animals’ right buccal pouches were treated with carcinogen for 9 weeks in one experimental and one control group and for 14 weeks in all other 3 groups. The animals of 2 experimental groups received sulindac from the 1st week and those of the third experimental group from the 10th week. After the end of carcinogenesis treated buccal pouches were removed and examined. In animals treated with carcinogen for 14 weeks development of oral SCC and tumor volume were significantly lower in animals that received sulindac from the first week of the experiment. Oral SCC developing in animals that received sulindac were more frequently well differentiated compared to the control group. In animals treated with carcinogen for 9 weeks the animals that received sulindac developed lower grade of epithelial dysplasia. Proliferation index Ki-67 and positivity for the antiapoptotic molecule survivin were lower in the animals that received sulindac. In conclusion, sulindac appears to exert antineoplastic effects in vivo in the HOCM.","abstract_has_math":false,"creators":["Katoumas, Konstantinos","Κατουμάς, Κωνσταντίνος"],"institution":"National and Kapodistrian University of Athens","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2015,"date_issued":"2015","date_published":"2015","updated_at":"2026-11-18T21:24:23Z","subjects":["Σουλινδάκη","ΜΣΑΦ","Ακανθοκυτταρικό καρκίνωμα στόματος","Μοντέλο καρκινογένεσης","Sulindac","NSAIDs","Squamous cell carcinoma","Carcinogenesis model","Ιατρική και Επιστήμες Υγείας","Βασική Ιατρική","Medical and Health Sciences","Basic Medicine"],"languages":["gre"],"rights":["BY_NC_ND"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["10.12681/eadd/36062"],"render_values":[{"text":"10.12681/eadd/36062","href":"https://doi.org/10.12681/eadd/36062","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/10442/hedi/36062","outbound_label":"Handle","outbound_source":"dc:identifier","record_url":"http://hdl.handle.net/10442/hedi/36062","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://phdtheses.ekt.gr/eadd_oai/request?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3A10442%2F36062","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Katoumas, Konstantinos","Κατουμάς, Κωνσταντίνος"]},{"key":"dc:creator.fathername","label":"Dc Creator Fathername","values":["Anastasios"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2015"]},{"key":"dc:publisher","label":"Institution","values":["National and Kapodistrian University of Athens","Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ)"]},{"key":"dc:type","label":"Dc Type","values":["PhD Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Σουλινδάκη","ΜΣΑΦ","Ακανθοκυτταρικό καρκίνωμα στόματος","Μοντέλο καρκινογένεσης","Sulindac","NSAIDs","Squamous cell carcinoma","Carcinogenesis model","Ιατρική και Επιστήμες Υγείας","Βασική Ιατρική","Medical and Health Sciences","Basic Medicine"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["gre"]},{"key":"dc:rights","label":"Dc Rights","values":["BY_NC_ND"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["10.12681/eadd/36062","http://hdl.handle.net/10442/hedi/36062"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["The purpose of the present study was to explore sulindac’s in vivo effects on oral squamous cell carcinoma (SCC) oncogenesis using the hamster cheek pouch oral carcinogenesis model (HOCM). Thirty Syrian golden hamsters were divided into 3 experimental and 2 control groups (n=6 each). The animals’ right buccal pouches were treated with carcinogen for 9 weeks in one experimental and one control group and for 14 weeks in all other 3 groups. The animals of 2 experimental groups received sulindac from the 1st week and those of the third experimental group from the 10th week. After the end of carcinogenesis treated buccal pouches were removed and examined. In animals treated with carcinogen for 14 weeks development of oral SCC and tumor volume were significantly lower in animals that received sulindac from the first week of the experiment. Oral SCC developing in animals that received sulindac were more frequently well differentiated compared to the control group. In animals treated with carcinogen for 9 weeks the animals that received sulindac developed lower grade of epithelial dysplasia. Proliferation index Ki-67 and positivity for the antiapoptotic molecule survivin were lower in the animals that received sulindac. In conclusion, sulindac appears to exert antineoplastic effects in vivo in the HOCM.","Σκοπός της παρούσας διδακτορικής διατριβής ήταν η μελέτη και μοριακή διερεύνηση της in vivo αντινεοπλασματικής δράσης της σουλινδάκης όσον αφορά στην πρόληψη και την θεραπεία της επιθηλιακής δυσπλασίας και του ακανθοκυτταρικού καρκίνου του στόματος (ΑΚΣ) στο μοντέλο καρκινογένεσης στον παρειακό θύλακο των Syrian golden hamsters (ΜΚΠΘ). Τριάντα πειραματόζωα χωρίστηκαν ανά 6 σε 3 πειραματικές και 2 ομάδες ελέγχου. Οι δεξιοί παρειακοί θύλακοι των ζώων επαλείφονταν με καρκινογόνο για 9 εβδομάδες σε μια πειραματική και μια ομάδα ελέγχου και για 14 εβδομάδες στις 3 υπόλοιπες ομάδες. Τα ζώα 2 πειραματικών ομάδων έλαβαν σουλινδάκη από την 1η εβδομάδα, ενώ εκείνα της τρίτης ομάδας από την 10η εβδομάδα. Στα ζώα στα οποία πραγματοποιήθηκε καρκινογένεση για 14 εβδομάδες, τα ζώα που έλαβαν σουλινδάκη από την πρώτη εβδομάδα εμφάνησαν μικρότερα ποσοστά ΑΚΣ και μικρότερο tumor volume. Η ανάπτυξη ΑΚΣ στα ζώα που έλαβαν σουλινδάκη ήταν συχνότερα καλής διαφοροποίησης σε σχέση με την ομάδα ελέγχου. Στα ζώα στα οποία πραγματοποιήθηκε καρκινογένεση για 9 εβδομάδες, τα ζώα που έλαβαν σουλινδάκη εμφάνισαν χαμηλότερου βαθμού επιθηλιακή δυσπλασία. Ο δείκτης πολλαπλασιασμού Ki-67 και η θετικότητα για το αντιαποπτωτικό μόριο επιβιωτίνη ήταν χαμηλότερα στα ζώα που έλαβαν σουλινδάκη. Συμπερασματικά η χορήγηση σουλινδάκης φαίνεται να εξασκεί in vivo αντινεοπλασματική δράση στο ΜΚΠΘ."]},{"key":"dc:title","label":"Title","values":["In vivo μελέτη της δράσης των αναστολέων της κυκλοοξυγενάσης σε πειραματικό μοντέλο καρκινογένεσης του στόματος","In-vivo analysis of the effects of cyclooxygenase inhibitors in an oral carcinogenesis model"]}]}],"canonical_facts":{"dc:creator":["Katoumas, Konstantinos","Κατουμάς, Κωνσταντίνος"],"dc:creator.fathername":["Anastasios"],"dc:date":["2015"],"dc:description":["The purpose of the present study was to explore sulindac’s in vivo effects on oral squamous cell carcinoma (SCC) oncogenesis using the hamster cheek pouch oral carcinogenesis model (HOCM). Thirty Syrian golden hamsters were divided into 3 experimental and 2 control groups (n=6 each). The animals’ right buccal pouches were treated with carcinogen for 9 weeks in one experimental and one control group and for 14 weeks in all other 3 groups. The animals of 2 experimental groups received sulindac from the 1st week and those of the third experimental group from the 10th week. After the end of carcinogenesis treated buccal pouches were removed and examined. In animals treated with carcinogen for 14 weeks development of oral SCC and tumor volume were significantly lower in animals that received sulindac from the first week of the experiment. Oral SCC developing in animals that received sulindac were more frequently well differentiated compared to the control group. In animals treated with carcinogen for 9 weeks the animals that received sulindac developed lower grade of epithelial dysplasia. Proliferation index Ki-67 and positivity for the antiapoptotic molecule survivin were lower in the animals that received sulindac. In conclusion, sulindac appears to exert antineoplastic effects in vivo in the HOCM.","Σκοπός της παρούσας διδακτορικής διατριβής ήταν η μελέτη και μοριακή διερεύνηση της in vivo αντινεοπλασματικής δράσης της σουλινδάκης όσον αφορά στην πρόληψη και την θεραπεία της επιθηλιακής δυσπλασίας και του ακανθοκυτταρικού καρκίνου του στόματος (ΑΚΣ) στο μοντέλο καρκινογένεσης στον παρειακό θύλακο των Syrian golden hamsters (ΜΚΠΘ). Τριάντα πειραματόζωα χωρίστηκαν ανά 6 σε 3 πειραματικές και 2 ομάδες ελέγχου. Οι δεξιοί παρειακοί θύλακοι των ζώων επαλείφονταν με καρκινογόνο για 9 εβδομάδες σε μια πειραματική και μια ομάδα ελέγχου και για 14 εβδομάδες στις 3 υπόλοιπες ομάδες. Τα ζώα 2 πειραματικών ομάδων έλαβαν σουλινδάκη από την 1η εβδομάδα, ενώ εκείνα της τρίτης ομάδας από την 10η εβδομάδα. Στα ζώα στα οποία πραγματοποιήθηκε καρκινογένεση για 14 εβδομάδες, τα ζώα που έλαβαν σουλινδάκη από την πρώτη εβδομάδα εμφάνησαν μικρότερα ποσοστά ΑΚΣ και μικρότερο tumor volume. Η ανάπτυξη ΑΚΣ στα ζώα που έλαβαν σουλινδάκη ήταν συχνότερα καλής διαφοροποίησης σε σχέση με την ομάδα ελέγχου. Στα ζώα στα οποία πραγματοποιήθηκε καρκινογένεση για 9 εβδομάδες, τα ζώα που έλαβαν σουλινδάκη εμφάνισαν χαμηλότερου βαθμού επιθηλιακή δυσπλασία. Ο δείκτης πολλαπλασιασμού Ki-67 και η θετικότητα για το αντιαποπτωτικό μόριο επιβιωτίνη ήταν χαμηλότερα στα ζώα που έλαβαν σουλινδάκη. Συμπερασματικά η χορήγηση σουλινδάκης φαίνεται να εξασκεί in vivo αντινεοπλασματική δράση στο ΜΚΠΘ."],"dc:identifier":["10.12681/eadd/36062","http://hdl.handle.net/10442/hedi/36062"],"dc:language":["gre"],"dc:publisher":["National and Kapodistrian University of Athens","Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ)"],"dc:rights":["BY_NC_ND"],"dc:subject":["Σουλινδάκη","ΜΣΑΦ","Ακανθοκυτταρικό καρκίνωμα στόματος","Μοντέλο καρκινογένεσης","Sulindac","NSAIDs","Squamous cell carcinoma","Carcinogenesis model","Ιατρική και Επιστήμες Υγείας","Βασική Ιατρική","Medical and Health Sciences","Basic Medicine"],"dc:title":["In vivo μελέτη της δράσης των αναστολέων της κυκλοοξυγενάσης σε πειραματικό μοντέλο καρκινογένεσης του στόματος","In-vivo analysis of the effects of cyclooxygenase inhibitors in an oral carcinogenesis model"],"dc:type":["PhD Thesis"]},"updated_at":"2026-11-18T21:24:23Z"}